Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 22 10 2018
accepted: 16 04 2019
pubmed: 26 4 2019
medline: 10 1 2020
entrez: 26 4 2019
Statut: ppublish

Résumé

Hyperuricemia has been associated with higher mortality in the general population, but less is known about CKD patients. The aim of our study was to determine the impact of elevated serum uric acid on cardiovascular mortality of CKD patients who later progress to hemodialysis. In this retrospective study, 120 CKD patients (entire population of patients with ESKD on January 1st, 2012) were observed from their first visit at the Nephrology outpatient clinic, while transitioning to hemodialysis, and until their death or January 1, 2016. After non-cardiovascular death exclusion, 83 CKD patients (33 female, 50 male) were left for further analysis. The average time of observation was 8.8 ± 4.2 years. Serum uric acid was measured regularly (every 3 months). No patients were treated for hyperuricemia. Mean uric acid of 420 µmol/L was set as a cut-off between normouricemic and hyperuricemic patients as per the laboratory's reference values. Survival rates were analyzed using Kaplan-Meier survival curves. Three Cox regression models were used to assess the influence of uric acid on survival. Mean uric acid was 379.8 ± 71.6 µmol/L (range 220-574). Sixty-three (75.9%) patients were normouricemic and 20 (24.1%) were hyperuricemic. Cholesterol was the only variable to show statistically significant difference (p = 0.004) between the groups. Bivariate analysis revealed an association between death and age, hyperuricemia, arterial hypertension, and history of cardiovascular disease. Kaplan-Meier survival analysis showed higher risk of cardiovascular death for hyperuricemic patients (log rank test; p < 0.0005). In Cox regression models, hyperuricemia remained a predictor of cardiovascular mortality (SE = 0.500, Exp(B) = 14.120, 95% CI 5.297-37.640) in our patients next to age and arterial hypertension. The results indicate an association between hyperuricemia and cardiovascular mortality in CKD patients who transition to hemodialysis.

Identifiants

pubmed: 31020628
doi: 10.1007/s11255-019-02154-w
pii: 10.1007/s11255-019-02154-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1013-1018

Références

Am J Physiol Renal Physiol. 2008 Oct;295(4):F1134-41
pubmed: 18701632
Kidney Int. 2011 Apr;79(7):765-72
pubmed: 21178980
Clin J Am Soc Nephrol. 2011 Oct;6(10):2470-7
pubmed: 21868616
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1039-44
pubmed: 22132954
Adv Chronic Kidney Dis. 2012 Nov;19(6):386-91
pubmed: 23089273
Nephrol Dial Transplant. 2013 Sep;28(9):2221-8
pubmed: 23543594
PLoS One. 2013 Nov 12;8(11):e76827
pubmed: 24265674
Curr Opin Rheumatol. 2014 Mar;26(2):186-91
pubmed: 24419750
South Med J. 2014 Apr;107(4):235-41
pubmed: 24937517
BMC Nephrol. 2014 Jul 27;15:122
pubmed: 25064611
Curr Rheumatol Rep. 2015 Mar;17(3):13
pubmed: 25740704
Nephrourol Mon. 2015 May 23;7(3):e27233
pubmed: 26290849
PLoS One. 2015 Dec 18;10(12):e0145193
pubmed: 26683302
Curr Rheumatol Rep. 2016 Jun;18(6):34
pubmed: 27105641
J Cardiol. 2016 Nov;68(5):384-391
pubmed: 27261247
Medicine (Baltimore). 2016 Jun;95(24):e3701
pubmed: 27310949
Curr Hypertens Rep. 2016 Oct;18(10):74
pubmed: 27696189
J Atheroscler Thromb. 2017 Jun 1;24(6):630-642
pubmed: 27784849
Clin Nephrol. 2017 Supplement 1;88(13):69-72
pubmed: 28601125
BMC Med. 2017 Jul 3;15(1):123
pubmed: 28669352
J Adv Res. 2017 Sep;8(5):551-554
pubmed: 28748121
Curr Med Res Opin. 2017 Nov;33(sup3):9-13
pubmed: 28952391
Acta Med Croatica. ;70(4-5):233-9
pubmed: 29087102
Am J Kidney Dis. 2018 Mar;71(3):362-370
pubmed: 29132945
Kidney Res Clin Pract. 2017 Dec;36(4):368-376
pubmed: 29285429
Am J Kidney Dis. 2018 Nov;72(5):728-744
pubmed: 29478869
PLoS One. 2018 Jul 2;13(7):e0199865
pubmed: 29966019
Clin Chim Acta. 2018 Nov;486:156-161
pubmed: 30076802

Auteurs

Tadej Petreski (T)

Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000, Maribor, Slovenia. tadej.petreski@gmail.com.

Robert Ekart (R)

Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000, Maribor, Slovenia.
Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000, Maribor, Slovenia.

Radovan Hojs (R)

Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000, Maribor, Slovenia.
Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000, Maribor, Slovenia.

Sebastjan Bevc (S)

Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000, Maribor, Slovenia.
Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000, Maribor, Slovenia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH